Your Product Innovation Begins Here: Booth 4555

NMN supplementation proved to mitigate radiotherapy-induced damages

Paid for by Effepharm Ltd

Scientific study validates NMN’s efficacy in alleviating intestinal damages caused by radiotherapy through reducing alterations to gut bacteria composition and function.

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”

The Global Regulatory Advantage Behind UTHEVER® NMN

Regulatory uncertainty remains one of the biggest challenges for NMN brands. Choosing the wrong ingredient could lead to compliance risks & market restrictions.

Discover UTHEVER® NMN’s Global Regulatory Landscape

NMN has long faced regulatory challenges. Today, that landscape is changing. We consistently invest in scientific research & quality development, aiming to establish UTHEVER® as the world’s most compliant NMN ingredient brand.